Investment firms The Carlyle Group Inc. (NASDAQ:CG) and SK Capital Partners, together with Beacon Parent Holdings, L.P., have ...

SOMERVILLE, Mass., June 02, 2025--bluebird bio (NASDAQ: BLUE) ("bluebird"), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by ...

With a better upfront offer on the table, enough bluebird bio investors have tendered their shares for the company's sale to ...

Carlyle and SK Capital have provided significant primary capital to support and scale bluebird’s commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia ...

(“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) today announced that the tender offer commenced on March 7, 2025 to acquire all of the ...

SK Capital is a transformational private investment firm with a disciplined focus on the life sciences, specialty materials, and ingredients sectors. The firm seeks to build resilient, sustainable ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

The nearly $6 billion BlueOval SK battery park is hard to miss from Interstate 65, just past the Glendale exit in Hardin ...

Sandisk has emerged from its spin-off with financial stability but now faces the challenge of proving its independence. Check ...

Expansion underscores South Korea’s strategic AI leadership and surging demand for ChatGPT Since the start of 2024, South ...